How much funding has Cognito Therapeutics raised?

Cognito Therapeutics has raised $198.0M in total funding, most recently a Series C round.

Who are Cognito Therapeutics's investors?

Cognito Therapeutics's investors include IAG Capital Partners, Starbloom Capital, Morningside Group, FoundersX Ventures, Alzheimer's Drug Discovery Foundation.

When was Cognito Therapeutics founded?

Cognito Therapeutics was founded in 2016.

Where is Cognito Therapeutics headquartered?

Cognito Therapeutics is headquartered in Cambridge, United States.

What industry is Cognito Therapeutics in?

Cognito Therapeutics operates in Biotech, Healthcare.

Cognito Therapeutics

Cambridge, United States · Founded 2016 · $198.0M raised

Biotech

Healthcare

Headquarters: Cambridge
Founded: 2016
Business Model: B2B2C
Website: cognitotx.com

Total Funding: $198.0M
Last Round: $105.0M Series CMar 2026
Rounds: 3

About

Cognito Therapeutics is a Cambridge, Massachusetts clinical-stage neurotechnology company founded in 2016 by MIT researchers Ed Boyden and Li-Huei Tsai, based on their discovery that sensory stimulation can evoke gamma-wave brain activity linked to Alzheimer's progression. Its non-invasive Spectris device delivers light-and-sound gamma stimulation and received FDA Breakthrough Device Designation in 2021; the company is advancing pivotal clinical trials aimed at slowing cognitive decline in Alzheimer's patients.

Summary

Cognito Therapeutics is a Biotech company based in Cambridge, United States, founded in 2016. It has raised $198.0M in total across 3 rounds, most recently a $105.0M Series C round in Mar 2026. Investors include IAG Capital Partners, Starbloom Capital and Morningside Group.

LinkedIn X (Twitter)